In summary, this study adopts 68Ga-PSMA PET/CT and mpMRI to locate target area of the visible prostate cancer, and SIB technology of CIRT to perform precise radical radiotherapy for localized prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.